Members of COR-LD have pioneered systematic review and meta-analysis for a number of liver diseases, specifically HCV and NASH. These assessments require extensive review of the literature followed by analysis according to PRISMA guidance. The systematic review data from members of COR-LD has been extensively cited in the literature and also forms the basis for extensive economic analysis performed by the team.
